Quince Therapeutics Past Earnings Performance

Past criteria checks 0/6

Quince Therapeutics's earnings have been declining at an average annual rate of -8.4%, while the Biotechs industry saw earnings growing at 12.3% annually.

Key information

-8.4%

Earnings growth rate

18.2%

EPS growth rate

Biotechs Industry Growth	17.0%
Revenue growth rate	n/a
Return on equity	-36.9%
Net Margin	n/a
Last Earnings Update	31 Dec 2023

Recent past performance updates

No updates

Recent updates

Here's Why We're Watching Quince Therapeutics' (NASDAQ:QNCX) Cash Burn Situation

Nov 21

Insider Buying: The Cortexyme, Inc. (NASDAQ:CRTX) Independent Director Just Bought 2.4% More Shares

Mar 10

Companies Like Cortexyme (NASDAQ:CRTX) Are In A Position To Invest In Growth

Feb 09

Cortexyme: A Fresh Perspective In Alzheimer's

Jan 12

Have Insiders Been Buying Cortexyme, Inc. (NASDAQ:CRTX) Shares This Year?

Dec 18

Revenue & Expenses Breakdown
Beta

How Quince Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGS:QNCX Revenue, expenses and earnings (USD Millions)
Date	Earnings	G+A Expenses	R&D Expenses
31 Dec 23	-31	15	9
30 Sep 23	-28	16	9
30 Jun 23	-31	16	10
31 Mar 23	-42	20	16
31 Dec 22	-52	25	25
30 Sep 22	-70	30	38
30 Jun 22	-83	33	49
31 Mar 22	-88	32	57
31 Dec 21	-90	30	61
30 Sep 21	-87	26	61
30 Jun 21	-87	23	64
31 Mar 21	-83	21	64
31 Dec 20	-77	18	61
30 Sep 20	-69	16	55
30 Jun 20	-57	13	47
31 Mar 20	-48	11	40
31 Dec 19	-37	9	30
30 Sep 19	-28	7	23
30 Jun 19	-21	5	17
31 Mar 19	-15	3	12
31 Dec 18	-12	2	10

Quality Earnings: QNCX is currently unprofitable.

Growing Profit Margin: QNCX is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: QNCX is unprofitable, and losses have increased over the past 5 years at a rate of 8.4% per year.

Accelerating Growth: Unable to compare QNCX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: QNCX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).

Return on Equity

High ROE: QNCX has a negative Return on Equity (-36.89%), as it is currently unprofitable.

Quince Therapeutics Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

Recent updates

Quince Therapeutics, Inc., Annual General Meeting, Jun 05, 2024

Quince Therapeutics, Inc. Launches Scientific Advisory Board

Quince Therapeutics, Inc. Appoints Rajiv Patni to Its Board of Directors

CEO & Director exercised options to buy US$336k worth of stock.

Independent Chairman of the board recently bought US$58k worth of stock

Quince Therapeutics Receives Written Notice from the Listing Qualifications Department of the Nasdaq Stock Market

Quince Therapeutics, Inc. Appoints Brendan Hannah to the Position of Chief Operating Officer

Insufficient new directors

New minor risk - Shareholder dilution

Quince Therapeutics, Inc. Appoints Luca Benatti as Director

Quince Therapeutics, Inc. (NasdaqGS:QNCX) acquired EryDel S.p.A. for approximately $510 million.

Quince Therapeutics, Inc. Announces That U.S. Food and Drug Administration Lifts the Partial Clinical Hold on Erydel S.P. A's Investigational New Drug (Ind) Application for Its Lead Phase 3 Asset, Erydex

Quince Therapeutics Appoints Charles S. Ryan as President

Independent Chairman of the board recently bought US$108k worth of stock

Quince Therapeutics, Inc. Announces the Departure of Karen Smith as Chief Medical Officer, Effective September 1, 2023

CEO, President & Director recently bought US$99k worth of stock

New minor risk - Share price stability

Quince Therapeutics, Inc. (NasdaqGS:QNCX) agreed to acquire EryDel S.p.A. for approximately $490 million.

Biomed Industries, Inc. submitted a proposal to acquire Quince Therapeutics, Inc. (NasdaqGS:QNCX) for $10.5 million.

Price target increased by 56% to US$12.00

Quince Therapeutics Gets an Initial Compliance Period of 180 Calendar Days to Regain Compliance with the Minimum Bid Price Requirement

Here's Why We're Watching Quince Therapeutics' (NASDAQ:QNCX) Cash Burn Situation

Insufficient new directors

Insufficient new directors

Quince Therapeutics, Inc. Presents Preclinical Data at OI 2022 Demonstrating Potential of a Targeted Anabolic for Accelerated Bone Healing of Osteogenesis Imperfecta Fractures

Price target increased to US$8.38

Cortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588

Cortexyme to change name and ticker symbol next month

Cortexyme, Inc. Announces Resignation of Leslie Holsinger as Executive Vice President of Research and Development, Effective July 31, 2022

Cortexyme, Inc.(NasdaqGS:CRTX) dropped from Russell 2000 Dynamic Index

Cortexyme, Inc. Announces Preclinical Data Demonstrating Efficacy of COR803 for the Treatment of Coronavirus Infections

Cortexyme, Inc. Appoints June Bray to its Board of Directors

Cortexyme, Inc. Announces Resignation of Christopher Lowe as Chief Financial Officer

Cortexyme, Inc. (NasdaqGS:CRTX) acquired Novosteo Inc. from David Lamond and others for $19.8 million.

Dr. Dirk Thye and Philip Low to Join Cortexyme Board

Price target decreased to US$7.60

Cortexyme, Inc. Reports Safety and Pharmacokinetics Results from Single Ascending Dose Portion of Its Phase 1 Clinical Trial of Cor588

Price target decreased to US$7.60

Cortexyme: A Biotech Worth A Look Based On Potential Alzheimer's Treatment

Cortexyme, Inc. Announces Executives Changes

Cortexyme, Inc. Receives Letter from the U.S. Food and Drug Administration, Placing Full Clinical Hold on Atuzaginstat’s (COR388) Investigational New Drug Application

Price target increased to US$44.00

Cortexyme: Drug Candidate COR588 May Offer Some Hope To Investors

We're Keeping An Eye On Cortexyme's (NASDAQ:CRTX) Cash Burn Rate

COO, CFO & Treasurer exercised options to buy US$387k worth of stock.

Cortexyme: A Challenging Path Forward

Cortexyme: Positive Lessons To Be Learned From Disappointing Results

Cortexyme And The Gingipain Hypothesis Of Alzheimer's Disease

COO, CFO & Treasurer exercised options and sold US$217k worth of stock

Cortexyme to Present Results from the GAIN Trial: A Phase 2/3 Study of Atuzaginstat in Mild to Moderate Alzheimer’s Disease at CTAD 2021

Cortexyme: Alzheimer's Readout In November A Binary Event

Cortexyme, Inc. Expands Proprietary Development Pipeline with Initiation of Phase 1 Clinical Trial of COR588

Price target increased to US$97.71

Cortexyme Presents New Data Demonstrating Evidence of P. Gingivalis Infection of the Central Nervous System in Alzheimer’s Disease at Annual Biomarkers for Alzheimer’s Disease Summit

We Think Cortexyme (NASDAQ:CRTX) Can Afford To Drive Business Growth

Price target increased to US$89.00

Price target increased to US$78.29

Cortexyme, Inc. Presents New Data Demonstrating Atuzaginstat Disrupts Biofilms and is Efficacious in Preclinical Models of Periodontal Disease at IADR 2021

COO, CFO & Treasurer exercised options and sold US$1.0m worth of stock

Cortexyme, Inc.(NasdaqGS:CRTX) dropped from Russell 3000E Value Index

Independent Director Kevin Young has left the company

Cortexyme Presents Updated Baseline Data from Complete Set of Participants Enrolled in Pivotal GAIN Trial at ASCP 2021 Annual Meeting

Cortexyme EPS beats by $0.02

We're Not Very Worried About Cortexyme's (NASDAQ:CRTX) Cash Burn Rate

Price target decreased to US$66.63

Independent Director recently bought US$1.7m worth of stock

Independent Director recently bought US$1.8m worth of stock

Insider Buying: The Cortexyme, Inc. (NASDAQ:CRTX) Independent Director Just Bought 2.4% More Shares

Cortexyme Announces Partnership with Parkinson Study Group

Price target lowered to US$66.63

Price target lowered to US$72.88

Cortexyme, Inc. Provides Regulatory Update on Development Program for Atuzaginstat in Alzheimer’s Disease

Cortexyme, Inc. Announces Executive Appointments

Companies Like Cortexyme (NASDAQ:CRTX) Are In A Position To Invest In Growth

Cortexyme: A Fresh Perspective In Alzheimer's

Revenue & Expenses Breakdown
Beta